Based on our current results, screening drugs that target IKZF3 amplification or IKZF3/HER2 co-amplification, which can be developed and introduced into clinical practice is of important significance to GC patients, this part is currently in progress. The gene discussed is IKZF3; the disease is gastric cancer.